: iStockAnalyst.com Symbols Feed

Analyst Comments: Allergan, Hitachi, Spectranetics, Alpharma, Conexant

Fri, 08 Aug 2008 20:55:00 GMT

Allergan, Inc. (AGN) has been expanding into new therapeutic areas through acquisitions over the past few quarters. We believe these acquisitions will provide the company with the opportunity to drive growth in its existing business and to expand into new areas of business even in the face of slowing U.S. consumer spend. The Inamed acquisition, in particular, should help strengthen Allergan's position as a specialty pharmaceutical company. From a fundamental standpoint, we are enthusiastic about the future of Allergan. The company possesses a strong blockbuster product in Botox wrinkle treatment and a slew of innovative new products in the eye and skin care markets. We were pleased to see Allergan receive the Food and Drug Administration approval for Juvederm dermal fillers several months ahead of expectations. Both Botox and Juvederm should help the company strengthen its position in the dermatology and[More...]

Analyst Comments: Tejon Ranch, Resource Capital, AutoZone, Andersons, PS Business Parks, Sonic Foundry, Macerich Company, Sunoco Logistics, Spectranetics

Mon, 07 Jul 2008 16:32:00 GMT

Management is pursuing the real estate development of the 270,000 acre Tejon Ranch Company (TRC) located in Southern California. The company's three major development projects are the Tejon Industrial Complex, Tejon Mountain Village and Centennial. As commercial, industrial and residential entitlements are pursued, the stock's valuation ought to expand significantly. The Buy rating is maintained. The company's prime asset is approximately 270,000 acres of contiguous, largely undeveloped land that...[More...]

Analyst Comments: SiRF Technology, Pfizer, ABM Industries, Semtech, CPFL Energia, Spectranetics, Public Storage, Digital River

Mon, 10 Mar 2008 20:02:14 GMT

SiRF Technology Holdings, Inc. (SIRF) is a fabless OEM of GPS semiconductor chipsets, semiconductor-based modules and associated software. SiRF reported December quarter results missed consensus expectations on the top- and bottom-line. Gross margin fell[More...]

A Hold on Spectranetics Corp.

Mon, 08 Oct 2007 16:40:15 GMT

Zacks healthcare industry analyst Tom Park has recently advised a Hold to the shares of medical equipment manufacturer Spectranetics Corporation (SPNC). Here are some of the reasons why: 'SPNC announced that it initiated the PATENT trial to assess patency and safety using the...[More...]

Spectranetics Posts Q3 Loss

Thu, 29 Oct 2009 00:47:00 GMT

Oct. 28--Spectranetics Corp. blamed $3.13 million in one-time costs for losses totaling $2.49 million, or 8 cents a share, in the third quarter.
Those costs included nearly $1.7 million related to a federal investigation into the company and related lawsuits.
The Colorado Springs-based medical laser manufacturer also reported $1.08 million in writeoffs from ending the smallest of three product lines it acquired in May 2008 from Kensey Nash Corp. and $366,000 in costs from a management restructuring that eliminated eight jobs, including the vice president of the company's vascular inventions unit.

: iStockAnalyst.com Symbols Feed

Analyst Comments: Allergan, Hitachi, Spectranetics, Alpharma, Conexant

Analyst Comments: Tejon Ranch, Resource Capital, AutoZone, Andersons, PS Business Parks, Sonic Foundry, Macerich Company, Sunoco Logistics, Spectranetics

Analyst Comments: SiRF Technology, Pfizer, ABM Industries, Semtech, CPFL Energia, Spectranetics, Public Storage, Digital River

A Hold on Spectranetics Corp.

Spectranetics Posts Q3 Loss

Glimmers of Improvement at Two Springs Tech Firms: Losses Narrow at Ramtron, Spectranetics

Management Changes Lead to Increased Spending on CEO Pay

Customs, FDA Agents Search Spectranetics; Trading Halted

Spectranetics Reports Third Quarter Revenue Up 7% to $28.8 Million

Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2009 Financial Results

Spectranetics to Present at Canaccord Adams’ 29th Annual Global Growth Conference on August 12

Spectranetics Reports Second Quarter Revenue of $29 Million

Spectranetics to Hold 2009 Second Quarter Financial Results Conference Call on July 23

Spectranetics Announces First Human Uses of Turbo-Tandem™ System

Spectranetics Announces FDA Clearance to Market Turbo-Tandem™ System

Spectranetics Names Jason Hein Senior VP, Sales, Marketing and Product Development

Spectranetics Receives CE Mark Approval for ThromCat®XT

Spectranetics Reports 15% Revenue Growth in First Quarter 2009

Form 4 Hein Jason D For: Jul 07 (10K)

Form 4 Boehme Lisa Renee For: Jul 07 (10K)

Form 3 Cain Thompson For: Jan 26 (10K)

Form 3 Boehme Lisa Renee For: Jun 25 (10K)

Form 4 Walker Craig W For: Jun 10 (10K)

Form 4 RUGGIO JOSEPH M For: Jun 10 (10K)

Form 4 JENNINGS WILLIAM C For: Jun 10 (10K)

Form 4 SPECTRANETICS CORP For: Jun 10 Filed by: FLETCHER R JOHN (10K)

Form 4 SPECTRANETICS CORP For: Jun 10 Filed by: BLACKBURN DAVID G (10K)

Form 4 Dowling Anne Melissa For: Jun 10 (10K)